Header Logo

Connection

Robin Jones to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Robin Jones has written about Treatment Outcome.
Robin Jones
Connection Strength
1.889
Treatment Outcome
  1. Future Directions in the Treatment of Osteosarcoma. Cells. 2021 01 15; 10(1).
    View in: PubMed
    Score: 0.097
  2. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 01; 20(1):132-141.
    View in: PubMed
    Score: 0.096
  3. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates Curr Treat Options Oncol. 2020 05 27; 21(7):55.
    View in: PubMed
    Score: 0.093
  4. Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy. Med Oncol. 2019 Dec 27; 37(2):13.
    View in: PubMed
    Score: 0.090
  5. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
    View in: PubMed
    Score: 0.088
  6. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan; 39(1):347-351.
    View in: PubMed
    Score: 0.084
  7. Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma. Med Oncol. 2018 Sep 05; 35(11):138.
    View in: PubMed
    Score: 0.082
  8. Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Med Oncol. 2018 Aug 20; 35(10):131.
    View in: PubMed
    Score: 0.082
  9. The current landscape of early drug development for patients with sarcoma in the immunotherapy era. Future Oncol. 2018 May; 14(12):1197-1211.
    View in: PubMed
    Score: 0.080
  10. Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. Anticancer Res. 2018 03; 38(3):1479-1483.
    View in: PubMed
    Score: 0.079
  11. Olaratumab in soft tissue sarcoma - Current status and future perspectives. Eur J Cancer. 2018 03; 92:33-39.
    View in: PubMed
    Score: 0.079
  12. Olaratumab for the treatment of soft-tissue sarcoma. Future Oncol. 2017 Oct; 13(24):2151-2157.
    View in: PubMed
    Score: 0.076
  13. Phase III Soft Tissue Sarcoma Trials: Success or Failure? Curr Treat Options Oncol. 2017 03; 18(3):19.
    View in: PubMed
    Score: 0.074
  14. Treatment of soft tissue sarcoma: a focus on earlier stages. Future Oncol. 2017 Jan; 13(1s):13-21.
    View in: PubMed
    Score: 0.073
  15. Understanding sarcomas and other rare tumors: an interview with Robin L Jones. Future Oncol. 2017 Feb; 13(5):391-394.
    View in: PubMed
    Score: 0.073
  16. Analysis of clinical prognostic factors for adult patients with head and neck sarcomas. Otolaryngol Head Neck Surg. 2014 Dec; 151(6):976-83.
    View in: PubMed
    Score: 0.063
  17. A Phase II multicenter, open-label, clinical and pharmokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. Invest New Drugs. 2014 Feb; 32(1):171-7.
    View in: PubMed
    Score: 0.059
  18. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol. 2013 Jun; 30(2):501.
    View in: PubMed
    Score: 0.056
  19. Nuclear NF-?B/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J Clin Pathol. 2011 Feb; 64(2):130-5.
    View in: PubMed
    Score: 0.048
  20. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(2):315-23.
    View in: PubMed
    Score: 0.043
  21. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006 Oct; 7(10):869-74.
    View in: PubMed
    Score: 0.036
  22. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005 Dec; 41(18):2853-60.
    View in: PubMed
    Score: 0.034
  23. Clinical and pathological absence of cardiotoxicity after liposomal doxorubicin. Lancet Oncol. 2004 Sep; 5(9):575-7.
    View in: PubMed
    Score: 0.031
  24. Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncol. 2021 Sep; 17(27):3627-3636.
    View in: PubMed
    Score: 0.025
  25. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer. 2021 09; 155:236-244.
    View in: PubMed
    Score: 0.025
  26. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. Eur J Surg Oncol. 2021 08; 47(8):2173-2181.
    View in: PubMed
    Score: 0.025
  27. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
    View in: PubMed
    Score: 0.024
  28. A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. Oncologist. 2020 12; 25(12):e2013-e2016.
    View in: PubMed
    Score: 0.024
  29. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. Cancer. 2020 01 01; 126(1):98-104.
    View in: PubMed
    Score: 0.022
  30. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opin Investig Drugs. 2019 Jun; 28(6):505-511.
    View in: PubMed
    Score: 0.021
  31. Safety and Efficacy Outcomes of Embolization in Hepatic Sarcomas. AJR Am J Roentgenol. 2018 Jan; 210(1):175-182.
    View in: PubMed
    Score: 0.019
  32. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
    View in: PubMed
    Score: 0.019
  33. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30; 388(10043):488-97.
    View in: PubMed
    Score: 0.018
  34. Advanced aggressive fibromatosis: Effective palliation with chemotherapy. Acta Oncol. 2011 Apr; 50(3):455-61.
    View in: PubMed
    Score: 0.012
  35. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov; 45(17):2930-4.
    View in: PubMed
    Score: 0.011
  36. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007 Dec; 106(2):181-9.
    View in: PubMed
    Score: 0.009
  37. Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 2007 Jan 01; 13(1):90-101.
    View in: PubMed
    Score: 0.009
  38. MYC amplification in breast cancer: a chromogenic in situ hybridisation study. J Clin Pathol. 2007 Sep; 60(9):1017-23.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.